BeiGene CEO John Oyler at an Endpoints News/PharmCube event in Shanghai, October 2018 (Credit: Endpoints News)

Am­gen takes a $2.7B stake in BeiGene, gain­ing a promi­nent al­ly in Chi­na to help seize a lead­ing role in can­cer drug com­mer­cial­iza­tion and de­vel­op­ment

Am­gen has found both a com­mer­cial part­ner to help build up its can­cer drug rev­enue in Chi­na, as well as a fast grow­ing R&D part­ner for the de­vel­op­ment of its ex­per­i­men­tal on­col­o­gy pipeline — in­clud­ing the close­ly-watched KRAS G12C drug AMG 510. And they’re pay­ing top dol­lar to close the deal to­day.

The big win­ner is BeiGene $BGNE, a Chi­nese man­u­fac­tur­er and de­vel­op­er who’s been hard at it grow­ing their port­fo­lio un­der CEO John Oyler. Oyler scored a deal that de­liv­ers $2.7 bil­lion to BeiGene in ex­change for 20.5% of the com­pa­ny — eq­ui­ty that Am­gen is pay­ing a sig­nif­i­cant pre­mi­um on at $174.85 per share. And Oyler will in­vest up to $1.25 bil­lion from his end to back work on a pipeline of rough­ly 20 more can­cer drugs in de­vel­op­ment from Am­gen.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA